UnitedHealth Group reported strong Q2 results with adjusted EPS rising nearly 30% and improved operating margins. The company raised its 2026 adjusted EPS guidance to $19.50–20.00 and increased its operating cash flow forecast by $6 billion, showing confidence in future growth. Additionally, UnitedHealth is accelerating its share buyback program, doubling the full-year target to $5 billion due to perceived undervaluation. Analysts maintain a 'Buy' rating, expecting a 38–39% upside in the next 12–16 months driven by earnings growth and margin recovery.
Luigi Mangione pleaded guilty in a New York federal court to stalking that led to the killing of UnitedHealthcare CEO Brian Thompson in December 2024. His plea came just weeks before a state trial for Thompson's murder was set to begin. Mangione face...
The Schwab U.S. Dividend Equity ETF (SCHD) focuses on high-quality companies with strong financials and a history of growing dividends, rather than chasing the highest yields. While its yield is around 3% to 4%, SCHD has delivered strong long-term re...
In 2026, the Schwab U.S. Dividend Equity ETF (SCHD) leads with a 25.6% year-to-date return, driven by its focus on current yield, value sectors, and energy exposure. Meanwhile, the Vanguard Dividend Appreciation ETF (VIG) prioritizes dividend growth ...
Luigi Mangione is expected to plead guilty in his federal stalking case related to the 2024 killing of UnitedHealthcare CEO Brian Thompson in Manhattan. The plea is scheduled during a pretrial conference in U.S. District Court, while Mangione also fa...
Over the past decade, iShares Core Dividend Growth ETF (DGRO) returned 257.35%, outperforming Schwab US Dividend Equity ETF (SCHD) which returned 235.33%. The difference stems from SCHD's stricter stock selection criteria requiring 10 years of consec...
